Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease

Journal of Clinical Psychopharmacology

Volumn 33, Issue 2, 2013, Pages 199-205

  Solé Padullés, Cristina ^a   Bartrés Faz, David ^b,c   Lladó, Albert ^a,c   Bosch, Beatriz ^a,c   Peña Gómez, Cleofé ^b   Castellví, Magdalena ^a   Rami, Lorena ^a,c   Bargalló, Nuria ^a,c   Sánchez Valle, Raquel ^a,c   Molinuevo, José Luis ^a,c  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Alzheimer disease; cholinesterase inhibitors; functional magnetic resonance imaging; memory encoding; resting state

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HUMAN; MALE; MEMORY; PARAHIPPOCAMPAL GYRUS; PRECUNEUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TEMPORAL GYRUS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CHOLINESTERASE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MAGNETIC RESONANCE IMAGING; MEMORY; PIPERIDINES; TIME FACTORS;

EID: 84874940626     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182825bfd     Document Type: Article

References (40)

1. Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm. 2006;113:1625-1644. (Pubitemid 44657659)
2. Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol. 2002;15:445-450. (Pubitemid 34828121)
3. Micheau J, Marighetto A. Acetylcholine and memory: a long, complex and chaotic but still living relationship. Behav Brain Res. 2011;10:424-429.
4. Alvarez A, Alarco R, Opazo C, et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci. 1998;18:3213-3223. (Pubitemid 28186014)
5. Inestrosa NC, Alvarez A, Dinamarca MC, et al. Acetylcholinesterase- amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway. Curr Alzheimer Res. 2005;2:301-306. (Pubitemid 40980188)
6. Nordberg A, Darreh-Shori T, Peskind E, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res. 2009;6:4-14.
7. Kaasinen V, Nagren K, JavenpaT, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol. 2002;22:615-620. (Pubitemid 35416788)
8. Tune L, Tiseo PJ, Ieni J, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry. 2003;11:169-177. (Pubitemid 36254190)
9. Teipel SJ, Drzezga A, Bartenstein P, et al. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology (Berl). 2006;187:86-94. (Pubitemid 43876920)
10. Nakano S, Asada T, Matsuda H, et al. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med. 2001;42:1441-1445. (Pubitemid 32953120)
11. Nobili F, Vitali P, Canfora M, et al. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol. 2002;113:1241-1248. (Pubitemid 34874515)
12. Shimizu S, Hanyu H, Iwamoto T, et al. SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease. J Neuroimaging. 2006;16:16-23. (Pubitemid 43238060)
13. Yoshida T, Ha-Kawa S, Yoshimura M, et al. Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease. Ann Nucl Med. 2007;21:257-265. (Pubitemid 350104523)
14. Saykin AJ, Wishart HA, Rabin LA, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain. 2004;127:574-1583.
15. Petrella JR, Prince SE, Krishnan S, et al. Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. AJNR Am J Neuroradiol. 2009;30:411-416.
16. Kircher TT, Erb M, Grodd W, et al. Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study. Am J Geriatr Psychiatry. 2005;13:1006-1013. (Pubitemid 46638668)
17. McGeown WJ, Shanks MF, Forbes-McKay KE, et al. Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease. Curr Alzheimer Res. 2010;7:415-427.
18. Greicius MD, Srivastava G, Reiss AL, et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA. 2004;30:4637-4642. (Pubitemid 38437463)
19. Wang L, Zang Y, He Y, et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage. 2006;31:496-504. (Pubitemid 43776683)
20. Zhang HY, Wang SJ, Xing J, et al. Detection of PCC functional connectivity characteristics in resting-state fMRI in mild Alzheimer's disease. Behav Brain Res. 2009;30:103-108.
21. Wu X, Li R, Fleisher AS, et al. Altered default mode network connectivity in Alzheimer's diseaseVa resting functional MRI and Bayesian network study. Hum Brain Mapp. 2011;32:1868-1881.
22. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1-38. (Pubitemid 351506788)
23. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;30:178-188.
24. Goveas JS, Xie C, Ward BD, et al. Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI. J Magn Reson Imaging. 2011;34:764-773.
25. Rami L, Goez-Anson B, Sanchez-Valle R, et al. Longitudinal study of amnesic patients at high risk for Alzheimer's disease: clinical, neuropsychological and magnetic resonance spectroscopy features. Dement Geriatr Cogn Disord. 2007;24:402-410. (Pubitemid 350036698)
26. SolePadulle C, LladoA, Bartre-Faz D, et al. Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Res. 2011;30:140-146.
27. SolePadulle C, Bartre-Faz D, JunqueC, et al. Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2009;30:1114-1124.
28. Calhoun VD, Adali T, Pearlson GD, et al. A method for making group inferences from functional MRI data using independent component analysis. Hum Brain Mapp. 2001;14:140-151. (Pubitemid 33032347)
29. Damoiseaux JS, Prater KE, Miller BL, et al. Functional connectivity tracks clinical deterioration in Alzheimer's disease. Neurobiol Aging. 2012;33:828.e19-828.e30.
30. Andrews-Hanna JR, Reidler JS, Sepulcre J, et al. Functional-anatomic fractionation of the brain's default network. Neuron. 2010;25:550-562.
31. Mesulam MM, Hersh LB, Mash DC, et al. Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: a choline acetyltransferase study. J Comp Neurol. 1992;15:316-328.
32. Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain function. Proc Natl Acad Sci USA. 2001;16:676-682. (Pubitemid 32105102)
33. Daselaar SM, Prince SE, Cabeza R. When less means more: deactivations during encoding that predict subsequent memory. Neuroimage. 2004;23:921-927. (Pubitemid 39446526)
34. Vannini P, O'Brien J, O'Keefe K, et al. What goes down must come up: role of the posteromedial cortices in encoding and retrieval. Cereb Cortex. 2011;21:22-34.
35. Sperling RA, Dickerson BC, Pihlajamaki M, et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 2010;12:27-43.
36. Bokde AL, Karmann M, Teipel SJ, et al. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. J Clin Psychopharmacol. 2009;29:147-156.
37. Shanks MF, McGeown WJ, Forbes-McKay KE, et al. Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease. Magn Reson Imaging. 2007;25:848-859. (Pubitemid 47081360)
38. McGeown WJ, Shanks MF, Venneri A. Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease. Neuropsychiatr Dis Treat. 2008;4:465-476. (Pubitemid 351711940)
39. Hampel H, Prvulovic D, Teipel SJ, et al. Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease. Prog Neurobiol. 2011;95:570-578.
40. Valenzuela M, Bartre-Faz D, Beg F, et al. Neuroimaging as endpoints in clinical trials: are we there yet Perspective from the first Provence workshop. Mol Psychiatry. 2011;31:1064-1066.